← All trials
NCT07124156
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 20, 2026
- Primary completion
- Jul 31, 2026
- Completion date
- Dec 31, 2026
- First posted
- Aug 15, 2025
- Last posted
- Nov 21, 2025
- Enrollment
- 24
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- European Vaccine Initiative (EVI), Heidelberg, GermanyLead sponsor
- Luxembourg Institute of HealthCollaborator
- Ifakara Health InstituteOfficial
- Ifakara Health InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.